QQQ   395.63 (+0.88%)
AAPL   192.77 (-1.50%)
MSFT   370.07 (-1.11%)
META   325.46 (-2.19%)
GOOGL   132.75 (-1.66%)
AMZN   146.11 (-0.89%)
TSLA   238.57 (-2.16%)
NVDA   468.22 (-1.44%)
NIO   7.58 (+2.71%)
BABA   71.53 (-0.85%)
AMD   133.80 (+3.79%)
T   16.72 (-1.18%)
F   11.13 (+1.09%)
MU   78.25 (+4.39%)
CGC   0.76 (-5.40%)
GE   120.25 (-0.28%)
DIS   92.50 (-0.34%)
AMC   7.10 (+2.45%)
PFE   28.53 (-0.87%)
PYPL   59.37 (+0.73%)
XOM   99.40 (-0.15%)
QQQ   395.63 (+0.88%)
AAPL   192.77 (-1.50%)
MSFT   370.07 (-1.11%)
META   325.46 (-2.19%)
GOOGL   132.75 (-1.66%)
AMZN   146.11 (-0.89%)
TSLA   238.57 (-2.16%)
NVDA   468.22 (-1.44%)
NIO   7.58 (+2.71%)
BABA   71.53 (-0.85%)
AMD   133.80 (+3.79%)
T   16.72 (-1.18%)
F   11.13 (+1.09%)
MU   78.25 (+4.39%)
CGC   0.76 (-5.40%)
GE   120.25 (-0.28%)
DIS   92.50 (-0.34%)
AMC   7.10 (+2.45%)
PFE   28.53 (-0.87%)
PYPL   59.37 (+0.73%)
XOM   99.40 (-0.15%)
QQQ   395.63 (+0.88%)
AAPL   192.77 (-1.50%)
MSFT   370.07 (-1.11%)
META   325.46 (-2.19%)
GOOGL   132.75 (-1.66%)
AMZN   146.11 (-0.89%)
TSLA   238.57 (-2.16%)
NVDA   468.22 (-1.44%)
NIO   7.58 (+2.71%)
BABA   71.53 (-0.85%)
AMD   133.80 (+3.79%)
T   16.72 (-1.18%)
F   11.13 (+1.09%)
MU   78.25 (+4.39%)
CGC   0.76 (-5.40%)
GE   120.25 (-0.28%)
DIS   92.50 (-0.34%)
AMC   7.10 (+2.45%)
PFE   28.53 (-0.87%)
PYPL   59.37 (+0.73%)
XOM   99.40 (-0.15%)
QQQ   395.63 (+0.88%)
AAPL   192.77 (-1.50%)
MSFT   370.07 (-1.11%)
META   325.46 (-2.19%)
GOOGL   132.75 (-1.66%)
AMZN   146.11 (-0.89%)
TSLA   238.57 (-2.16%)
NVDA   468.22 (-1.44%)
NIO   7.58 (+2.71%)
BABA   71.53 (-0.85%)
AMD   133.80 (+3.79%)
T   16.72 (-1.18%)
F   11.13 (+1.09%)
MU   78.25 (+4.39%)
CGC   0.76 (-5.40%)
GE   120.25 (-0.28%)
DIS   92.50 (-0.34%)
AMC   7.10 (+2.45%)
PFE   28.53 (-0.87%)
PYPL   59.37 (+0.73%)
XOM   99.40 (-0.15%)

BioXcel Therapeutics (BTAI) Stock Price, News & Analysis

$3.16
-0.01 (-0.32%)
(As of 01:57 PM ET)
Compare
Today's Range
$3.07
$3.36
50-Day Range
$2.32
$5.51
52-Week Range
$2.23
$34.13
Volume
430,879 shs
Average Volume
1.88 million shs
Market Capitalization
$92.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.88

BioXcel Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
655.5% Upside
$23.88 Price Target
Short Interest
Healthy
25.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.13
Upright™ Environmental Score
News Sentiment
-0.68mentions of BioXcel Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.19) to ($2.95) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

194th out of 943 stocks

Biotechnology Industry

5th out of 44 stocks


BTAI stock logo

About BioXcel Therapeutics Stock (NASDAQ:BTAI)

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BTAI Stock Price History

BTAI Stock News Headlines

Unlocking AI investment opportunities in healthcare (BTAI)
AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Q3 2023 BioXcel Therapeutics Inc Earnings Call
Recap: BioXcel Therapeutics Q3 Earnings
BioXcel Therapeutics Inc BTAI
See More Headlines
Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/14/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BTAI
Fax
N/A
Employees
183
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$23.88
High Stock Price Target
$40.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+657.9%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
7 Analysts

Profitability

Net Income
$-165,760,000.00
Net Margins
-17,037.44%
Pretax Margin
-17,037.60%

Debt

Sales & Book Value

Annual Sales
$380,000.00
Book Value
$2.74 per share

Miscellaneous

Free Float
18,793,000
Market Cap
$92.20 million
Optionable
Not Optionable
Beta
0.78

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Vimal D. Mehta Ph.D. (Age 62)
    Founder, CEO, President, & Director
    Comp: $1.76M
  • Mr. Javier Rodriguez (Age 51)
    Senior VP, Chief Legal Officer & Corporate Secretary
    Comp: $638.88k
  • Mr. Matthew Wiley (Age 51)
    Senior VP & Chief Commercial Officer
    Comp: $620.12k
  • Mr. Richard I. Steinhart MBA (Age 66)
    Senior VP & CFO
    Comp: $404k
  • Dr. Frank D. Yocca Ph.D. (Age 67)
    Senior VP & Chief Scientific Officer
    Comp: $452.58k
  • Dr. Vincent J. O'Neill B.Sc. (Age 54)
    M.D., M.R.C.P., Senior VP & Chief Medical Officer
    Comp: $510.17k
  • Dr. Chetan D. Lathia Ph.D.
    Senior VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs
  • Dr. Robert Risinger M.D.
    Chief Medical Officer - Neuroscience
  • Mr. Robert Scala (Age 54)
    Vice President of Commercial Operations & Launch Planning
  • Dr. Friso Postma
    Senior Director of Neuroscience & Artificial intelligence














BTAI Stock Analysis - Frequently Asked Questions

Should I buy or sell BioXcel Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BTAI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTAI, but not buy additional shares or sell existing shares.
View BTAI analyst ratings
or view top-rated stocks.

What is BioXcel Therapeutics' stock price target for 2024?

7 Wall Street research analysts have issued 12 month price targets for BioXcel Therapeutics' shares. Their BTAI share price targets range from $11.00 to $40.00. On average, they expect the company's stock price to reach $23.88 in the next year. This suggests a possible upside of 655.5% from the stock's current price.
View analysts price targets for BTAI
or view top-rated stocks among Wall Street analysts.

How have BTAI shares performed in 2023?

BioXcel Therapeutics' stock was trading at $21.48 on January 1st, 2023. Since then, BTAI shares have decreased by 85.3% and is now trading at $3.16.
View the best growth stocks for 2023 here
.

Are investors shorting BioXcel Therapeutics?

BioXcel Therapeutics saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 5,080,000 shares, a decline of 12.6% from the October 31st total of 5,810,000 shares. Based on an average daily volume of 3,130,000 shares, the short-interest ratio is currently 1.6 days. Approximately 25.1% of the shares of the stock are short sold.
View BioXcel Therapeutics' Short Interest
.

When is BioXcel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our BTAI earnings forecast
.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) posted its quarterly earnings results on Tuesday, November, 14th. The company reported ($1.72) EPS for the quarter, missing the consensus estimate of ($1.29) by $0.43. The business had revenue of $0.34 million for the quarter, compared to analyst estimates of $0.84 million. BioXcel Therapeutics had a negative net margin of 17,037.44% and a negative trailing twelve-month return on equity of 890.63%.

What ETF holds BioXcel Therapeutics' stock ?

iShares Neuroscience and Healthcare ETF holds 2,477 shares of BTAI stock, representing 0.39% of its portfolio.

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (9.23%), Ameriprise Financial Inc. (2.28%), Northern Trust Corp (0.77%), Adage Capital Partners GP L.L.C. (0.68%), Charles Schwab Investment Management Inc. (0.47%) and Bank of New York Mellon Corp (0.44%). Insiders that own company stock include Bioxcel Llc, Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Richard I Steinhart, Vimal Mehta and Vincent O'neill.
View institutional ownership trends
.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BTAI) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -